This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study
Journal of Translational Medicine Open Access 11 December 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hurko, O. & Jones, G. K. Valuation of biomarkers. Nature Rev. Drug Discov. 10, 253–254 (2011).
Boise, L. et al. Dementia assessment in primary care: results from a study in three managed care systems. J. Gerontol. A Biol. Sci. Med. Sci. 59, M621–M626 (2004).
Hampel, H. et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature Rev. Drug Discov. 9, 560–574 (2010).
Beckett, L. A. et al. The Alzheimer's disease neuroimaging initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement. 6, 257–264 (2010).
Dimasi, J. A. et al. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272–277 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Eric M. Snyder is an employee of Leerink Swann Consulting LLC, which serves a large number of pharmaceutical and biotech clients worldwide.
Frank S. David is an employee of Leerink Swann Consulting LLC, a life sciences consultancy that serves a large number of biopharmaceutical, medical technology, tools and diagnostics companies worldwide.
Jake Olin is an employee of Leerink Swann Consulting LLC, a life sciences consultancy that serves a large number of biopharmaceutical, medical technology, tools and diagnostics companies worldwide.
Supplementary information
Supplementary information S1
Impact of a diagnostic on the profit and loss calculation for an AD therapy (PDF 601 kb)
Rights and permissions
About this article
Cite this article
Snyder, E., Olin, J. & David, F. Maximizing the value of diagnostics in Alzheimer's disease drug development. Nat Rev Drug Discov 11, 183–184 (2012). https://doi.org/10.1038/nrd3535
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3535